Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4160MR)

This product GTTS-WQ4160MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4160MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7668MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ6648MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ15334MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ5675MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ7849MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ1901MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ5076MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ9062MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW